title: Editorial update on emerging treatments of atopic dermatitis.
abstract: Various new agents are in the research pipeline for atopic dermatitis. These include IL-4 receptor antagonist, cis-urocanic acid, κ-opiod receptor agonist, neurokinin receptor antagonist and antimicrobial peptide. The current review updates the status of these clinical trials and provides insight into other potential molecular targets including IL-22 and TLR-2.
authors.forename: Peck Y
authors.initials: PY
authors.lastname: Ong
mesh_terms: D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007378:Interleukins / Q000378:metabolism; D058990:Molecular Targeted Therapy; D051195:Toll-Like Receptor 2 / Q000378:metabolism; D000097043:Interleukin-22
chemical_list: D007378:Interleukins; D051195:Toll-Like Receptor 2; D000097043:Interleukin-22